Literature DB >> 16313288

Effects of highly active antiretroviral therapy on paediatric metabolite levels.

M P Rhoads1, C J Smith, G Tudor-Williams, P Kyd, S Walters, C A Sabin, E G H Lyall.   

Abstract

OBJECTIVES: Highly active antiretroviral therapy (HAART) has extended survival of HIV-infected children into adulthood, raising concerns about long-term metabolic changes in childhood.
METHODS: A longitudinal study of metabolite levels in paediatric HIV-infected patients before and after starting HAART (January 2000 to June 2003). The effects of HAART on nonfasting blood levels of total (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol, cholesterol ratio and lactate were analysed using mixed-effects regression.
RESULTS: A total of 146 children attended 1208 appointments (median 6.7/child). Of these, 99 (68%) were African. At baseline, 75 (51%) were on HAART and had higher TC (4.19 vs 3.49 mmol/L, P<0.0001), HDL (1.03 vs 0.82 mmol/L, P<0.0001), and LDL (2.54 vs 2.11 mmol/L, P=0.0003) than those not on HAART. Metabolites increased with time on HAART exposure and then stabilized. At 2 years, TC had increased by 0.93 mmol/L (P<0.0001), with 29 children (20%) having repeated TC levels above the 95th centile. LDL and HDL had increased by 0.69 and 0.31 mmol/L at 2 years, respectively (both P<0.0001). Lactates declined with increasing age (-0.06 mmol/L/year, P=0.0001).
CONCLUSIONS: This is the first cohort study to demonstrate significant elevations of HDL as well as LDL in children on HAART. This rise in cardio-protective HDL may represent a positive effect of treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16313288     DOI: 10.1111/j.1468-1293.2005.00337.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  6 in total

1.  Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study.

Authors:  Denise L Jacobson; Paige Williams; Katherine Tassiopoulos; Ann Melvin; Rohan Hazra; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

2.  Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.

Authors:  Agnes Langat; Sarah Benki-Nugent; Dalton Wamalwa; Ken Tapia; Evelyn Ngugi; Lara Diener; Barbra A Richardson; Ann Melvin; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

3.  Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Authors:  Katherine Tassiopoulos; Paige L Williams; George R Seage; Marilyn Crain; James Oleske; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

4.  Treatment of pediatric HIV infection.

Authors:  Elisa A d'Oulx; Elena Chiappini; Maurizio de Martino; Pier-Angelo Tovo
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

5.  Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.

Authors:  Caroline J Chantry; Michael D Hughes; Carmelita Alvero; Joseph S Cervia; William A Meyer; Janice Hodge; Peggy Borum; Jack Moye
Journal:  Pediatrics       Date:  2008-06-02       Impact factor: 7.124

6.  Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.

Authors:  J Jao; W Yu; K Patel; T L Miller; B Karalius; M E Geffner; L A DiMeglio; A Mirza; J S Chen; M Silio; E J McFarland; R B Van Dyke; D Jacobson
Journal:  HIV Med       Date:  2017-11-21       Impact factor: 3.180

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.